A new US Food and Drug Administration (FDA) policy may help bring biosimilar insulins to market more quickly. (Biosimilars are biologic medical products that are highly similar to another already approved biological medicine.) However, analysts say there is no guarantee that the products will be significantly less expensive than branded insulins. Read more